Despite significant progress in breast cancer (BC) therapy, it is globally the most commonly
diagnosed cancer and leads to the death of over 650,000 women annually. Androgen …

Triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) are amongst
the most aggressive forms of solid tumors. TNBC is highlighted by absence of genetic …

Background Triple-negative breast cancer (TNBC) represents up to 20% of all breast
cancers. This cancer lacks the expression of the estrogen receptor, progesterone receptor …

Triple negative breast cancer (TNBC) is an aggressive breast cancer with historically poor
outcomes, primarily due to the lack of effective targeted therapies. The tumor molecular …

The Androgen Receptor (AR) is emerging as an important factor in the pathogenesis of
breast cancer (BC), which is the most common malignancy among females worldwide. The …

Abstract Lessons Learned The combination of enobosarm and pembrolizumab was well
tolerated and showed a modest clinical benefit rate of 25% at 16 weeks. Future trials …

The androgen receptor (AR) is a drug target in breast cancer, and AR-targeted therapies
have induced tumor responses in breast cancer patients. In this review, we summarized the …

Androgen receptor (AR) is expressed in 60-70% of breast cancers (BCs) and the availability
of anti-AR compounds, currently used for treating prostate cancer, paves the way to tackle …

Simple Summary Nowadays, the upfront treatment for patients facing a diagnosis of
advanced luminal breast cancer (BC) is a combination of endocrine therapy (ET) with an …

Apocrine carcinoma of the breast is a rare malignancy. According to 2019 WHO
classification, apocrine cellular features and a characteristic steroid receptor profile …